SCHEMBL17744014

SCHEMBL17744014

CCC=CCCCCCCC(O)CCCCCCCC=CCC=CCCCCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.53
FFAR4 Q5NUL3 3/20 0.53
ALDH1A1 P00352 7/20 0.50
F7 P08709 5/20 0.50
F3 P13726 5/20 0.50
KDM4E B2RXH2 4/20 0.50
CYP19A1 P11511 3/20 0.50
PPARG P37231 3/20 0.50
PPARD Q03181 3/20 0.50
PPARA Q07869 3/20 0.50
OXER1 Q8TDS5 2/20 0.50
MAPT P10636 2/20 0.50
LMNA P02545 2/20 0.50
CYP3A4 P08684 2/20 0.50
HPGD P15428 2/20 0.50
ALOX15 P16050 2/20 0.50
PTGS1 P23219 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
NFKB1 P19838 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16503983 1.00 FFAR1 (0.53) FFAR1FFAR4ALDH1A1F7F3
SCHEMBL17744013 1.00 FFAR1 (0.53) FFAR1FFAR4ALDH1A1F7F3
SCHEMBL23704055 1.00 FFAR1 (0.53) FFAR1FFAR4ALDH1A1F7F3
SCHEMBL15317873 0.94 FFAR1 (0.57) FFAR1FFAR4ALDH1A1F7F3
SCHEMBL44603 0.94 FFAR1 (0.57) FFAR1FFAR4ALDH1A1F7F3
SCHEMBL10133212 0.94 FFAR1 (0.57) FFAR1FFAR4ALDH1A1F7F3
SCHEMBL6037208 0.94 FFAR1 (0.57) FFAR1FFAR4ALDH1A1F7F3
SCHEMBL21197440 0.94 FFAR1 (0.57) FFAR1FFAR4ALDH1A1F7F3
SCHEMBL20603893 0.94 FFAR1 (0.57) FFAR1FFAR4ALDH1A1F7F3
SCHEMBL12186743 0.94 FFAR1 (0.57) FFAR1FFAR4ALDH1A1F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10731159-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-08-04 US disclosed
US-20200080086-A1 CATIONIC LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-03-12 US disclosed
EP-3020701-B1 NOVEL LIPID DAIICHI SANKYO CO LTD (JP) 2018-09-26 EP disclosed
US-20180051285-A1 CATIONIC LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-02-22 US disclosed
US-9803199-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-10-31 US disclosed
US-20160257951-A1 NOVEL LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-08 US disclosed
EP-3020701-A1 NOVEL LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257951-A1 NOVEL LIPID NPC1L1, CETP, LIPC FFAR1 183/4885FFAR4 195/4885ALDH1A1 1863/4885
US-20180051285-A1 CATIONIC LIPID CETP, NPC1L1, LIPA FFAR1 161/4885FFAR4 175/4885ALDH1A1 2540/4885
US-20200080086-A1 CATIONIC LIPID CETP, NPC1L1, LIPA FFAR1 161/4885FFAR4 175/4885ALDH1A1 2540/4885
US-10731159-B2 Cationic lipid CETP, NPC1L1, LIPA FFAR1 161/4885FFAR4 175/4885ALDH1A1 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.